Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Combination therapies for certain malignancies discussed by Idec

June 29, 2001

Phase I/II bladder cancer trial shows 59% complete response rate on MCC therapy

June 26, 2001

Phase I/II trial begins for malignant melanoma vaccine

June 26, 2001

Second multicenter phase I/II trial of GVAX for NSCLC

June 22, 2001

Patient enrollment completed in phase III trial of CeaVac

June 21, 2001

MabThera monoclonal antibody approved in Japan

June 21, 2001

ImClone reaches second milestone in phase III evaluation of BEC2

June 19, 2001

Phase III comparative trial of PEG-Intron and Intron A for CML completed

June 14, 2001

Extension of pemtumomab phase III trial announced following meeting with FDA

June 12, 2001

Dendreon expands phase III trials of Provenge for prostate cancer

June 12, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...